|
C1ORF26 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63613567139009E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.05249142734465E-13 |
| Normal-vs-Stage2 |
4.16333634234434E-14 |
| Normal-vs-Stage3 |
1.626032641866E-12 |
| Normal-vs-Stage4 |
1.11022302462516E-16 |
| Stage1-vs-Stage2 |
2.478800E-01 |
| Stage1-vs-Stage3 |
5.151900E-02 |
| Stage1-vs-Stage4 |
1.154240E-02 |
| Stage2-vs-Stage3 |
7.780000E-01 |
| Stage2-vs-Stage4 |
2.406800E-01 |
| Stage3-vs-Stage4 |
3.266000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.63757896132211E-12 |
| Normal-vs-AfricanAmerican |
1.5092038729847E-11 |
| Normal-vs-Asian |
4.99711383383783E-12 |
| Caucasian-vs-AfricanAmerican |
9.137800E-01 |
| Caucasian-vs-Asian |
5.140800E-01 |
| AfricanAmerican-vs-Asian |
7.134600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.88338275267597E-15 |
| Normal-vs-Female |
1.38777878078145E-14 |
| Male-vs-Female |
6.618000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.90825133472572E-12 |
| Normal-vs-Age(41-60Yrs) |
2.66453525910038E-15 |
| Normal-vs-Age(61-80Yrs) |
1.62814206561279E-12 |
| Normal-vs-Age(81-100Yrs) |
6.11899999999332E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.692000E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.833600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.747800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.992400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.951200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.319400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.855900E-02 |
| Classical-VS-Follicular |
1.981650E-01 |
| Classical-VS-Other |
5.059600E-01 |
| Classical-VS-Normal |
5.78870285039557E-13 |
| Tall-VS-Follicular |
2.018400E-01 |
| Tall-VS-Other |
6.544600E-01 |
| Tall-VS-Normal |
1.64313007644523E-14 |
| Follicular-VS-Other |
8.466400E-01 |
| Follicular-VS-Normal |
1.03583808197527E-13 |
| Other-VS-Normal |
3.153700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.63946634046397E-12 |
| Normal-vs-N1 |
2.55351295663786E-15 |
| N0-vs-N1 |
1.157990E-01 |
|
|
